[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02170298 : Lisdexamfetamine's Effect In ADHD in the Brain and Cognition|
|Ages||Min: 12 Years Max: 30 Years|
1. The subject is a male or female adolescent or young adult, between the ages of 12 and
30 (inclusive) at the time of the initial signing of the informed consent/assent
2. The subject meets DSM Fifth edition (DSM-5) diagnostic criteria for Attention
Deficit-Hyperactivity Disorder, Combined-Type. Diagnostic Interviews and Rating
Scales will be used to inform about DSM criteria. Participants with 4 or 5
hyperactive/impulsive symptoms may be included at the investigator's discretion.
3. This includes a history of childhood symptoms of ADHD for the adult subjects
4. The subject, a caregiver, and the investigator must all agree that the present ADHD
symptoms cause impairment in the subject's normal routines, which include academic
achievement, occupational functioning, social activities, and/or relationships
5. Females of childbearing potential (defined by menarche and not having undergone
surgical sterilization/hysterectomy) must have a negative pregnancy test, must be
practicing acceptable methods of contraception (or can confirm abstinence at each
scheduled visit), and must not be pregnant or lactating at any point while they are
participating in the study.
6. Written informed consent must be obtained from a legally acceptable representative
(e.g. guardian or caregiver for minors), in accordance with requirements of the
Institutional Review Board (IRB), prior to the initiation of any protocol-required
procedures. In addition, the subject, as required by the IRB, must provide informed
assent at screening and as such must be able to understand that he or she can
withdraw from the time at any time.
7. The subject and the designated guardian(s) or caregiver(s)[If minors] are able to
comprehend and satisfactorily comply with the protocol requirements, as evaluated by
- Clinical contraindications
1. History of schizophrenia, bipolar disorder, autism spectrum disorder, specific
or focal neurological disorder
2. Current academic learning disorder(s)
3. Abnormal cardiac functioning with be excluded
4. The subject experiences Adverse Events during the trial that would, in the
investigator's judgment, preclude further exposure to LDX
5. The subject had protocol violations during the trial considered major in the
judgment of the investigator (significant noncompliance, use of prohibited
concomitant medications, concern with use of drugs of abuse, etc.), which would
deem them poor candidates for this trial
6. Sexually active males who will not commit to utilizing an approved birth control
methods or who will not remain abstinent during the trial and for 90 days
following the last dose of study drug. Sexually active females of childbearing
potential who will not commit to utilizing 1 of the approved birth control
methods or who will not remain abstinent during the trial and for 30 days
following the last dose of study drug. Abstinence will be permitted if it is
confirmed and documented at every trial visit. If employing birth control, 1 of
the following precautions must be used: vasectomy, tubal ligation, vaginal
diaphragm, intrauterine device, birth control pill, birth control depot
injections, implant, condom or sponge with spermicide.
7. Subjects with an inability to swallow tablets or tolerate oral medication
8. It is in the investigator's opinion that it is not in the subject's best
interest to continue
9. Contraindication for MRI scanning (e.g., metal implants, pacemakers, metal
foreign bodies, pregnancy)
- Beast-feeding (if applicable)
1. Females who are breast-feeding and/or who have a positive pregnancy test result
prior to receiving trial drug
- Excluded medications
1. Agents that lower blood levels of amphetamines: urinary acidifying agents (e.g.
ammonium chloride, sodium acid phosphate, etc.); Methenamine Therapy.
2. Agents that increase blood levels of amphetamines: urinary alkalinizing agents
(e.g. Acetazolamide, some Thiazides).
3. Dextroamphetamine is known to inhibit monoamine oxidase, as well as a metabolite
of furazolidone. Concurrent administration of monoamine oxidase (MAOI)
inhibitors is contraindicated because MAOIs potentially can result in
hypertensive crisis. Vyvanse should not be given for at least 14 days after
discontinuation of an MAO inhibitor.
4. Agents whose effects may be reduced by amphetamines: Adrenergic blockers,
Antihistamines, Antihypertensives, Veratrum Alkaloids, Ethosuximide.
5. Agents whose effects may be potentiated by amphetamines: Tricyclic
antidepressants, meperidine, Norepinephrine, Phenobarbital, Phenytoin.
6. Agents that may reduce the effects of amphetamines: Antipsychotics, Lithium
- Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or
1. Previous negative history with LDX
- Active drug or alcohol use or dependence that, in the opinion of the site
investigator, would interfere with adherence to study requirements
1. A positive drug screen for cocaine or other drugs of abuse (excluding caffeine,
nicotine or prescribed psychostimulants for ADD/ADHD)
2. History of substance dependence or abuse disorder currently or within past 5
- Recent serious illness requiring systemic treatment and/or hospitalization prior to
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02170298
| Link to official Clinicaltrials.gov listing